{"id":2041,"date":"2026-08-05T15:47:07","date_gmt":"2026-08-05T07:47:07","guid":{"rendered":"https:\/\/www.millibuff.com\/?p=2041"},"modified":"2026-08-05T15:47:07","modified_gmt":"2026-08-05T07:47:07","slug":"%e5%b0%8f%e7%89%9b%e6%b4%9e%e5%af%9f-menin%e6%8a%91%e5%88%b6%e5%89%82%ef%bc%9a%e4%bb%8e%e6%9c%ba%e5%88%b6%e9%9d%b6%e7%82%b9%e5%88%b0%e5%a4%8d%e5%8f%91%e9%9a%be%e6%b2%bb%e7%99%bd%e8%a1%80%e7%97%85","status":"publish","type":"post","link":"https:\/\/www.millibuff.com\/?p=2041","title":{"rendered":"\u5c0f\u725b\u6d1e\u5bdf | Menin\u6291\u5236\u5242\uff1a\u4ece\u673a\u5236\u9776\u70b9\u5230\u590d\u53d1\u96be\u6cbb\u767d\u8840\u75c5\u6cbb\u7597\u65b0\u683c\u5c40"},"content":{"rendered":"\n

\u4e00\u3001\u5206\u5b50\u673a\u5236\uff1aMenin-KMT2A\u8f74\u4e3a\u4f55\u6784\u6210\u767d\u8840\u75c5”\u53ef\u9776\u5411\u7684\u81f4\u764c\u4f9d\u8d56”<\/h2>\n\n\n\n

\u6025\u6027\u767d\u8840\u75c5\u7684\u6076\u6027\u8868\u578b\u9ad8\u5ea6\u4f9d\u8d56Menin-KMT2A\u8f6c\u5f55\u8c03\u63a7\u8f74\u3002Menin\u4f5c\u4e3a\u652f\u67b6\u86cb\u767d\uff0c\u53c2\u4e0e\u67d3\u8272\u8d28\u590d\u5408\u7269\u7ec4\u88c5\uff0c\u7ef4\u6301HOXA\u57fa\u56e0\u7c07\u4e0eMEIS1\u7684\u6301\u7eed\u8868\u8fbe\u3002\u5728\u643a\u5e26KMT2A\u91cd\u6392\uff08KMT2Ar\uff09\u53caNPM1\u7a81\u53d8\uff08NPM1m\uff09\u7684\u6025\u6027\u9ad3\u7cfb\u767d\u8840\u75c5\uff08AML\uff09\u4e2d\uff0c\u8be5\u4f9d\u8d56\u6027\u8868\u73b0\u6700\u4e3a\u663e\u8457\uff1aMenin\u4e0eKMT2A\u878d\u5408\u86cb\u767d\u5f02\u5e38\u7ed3\u5408\uff0c\u6301\u7eed\u6fc0\u6d3bHOX\/MEIS1\u81f4\u764c\u8f6c\u5f55\u73af\u8def\uff0c\u652f\u6491\u767d\u8840\u75c5\u5e72\u7ec6\u80de\u81ea\u6211\u66f4\u65b0\u3001\u963b\u6ede\u9ad3\u7cfb\u7ec6\u80de\u6b63\u5e38\u5206\u5316[3]\u3002<\/p>\n\n\n\n

\u5173\u952e\u8ba4\u8bc6<\/strong>\uff1a\u4e0a\u8ff0\u81f4\u764c\u4f9d\u8d56\u5e76\u4e0d\u5c40\u9650\u4e8eKMT2Ar\u3001NPM1m AML\uff0c\u540c\u6837\u8986\u76d6NUP98\u91cd\u6392\u3001UBTF\u4e32\u8054\u91cd\u590d\u7b49\u5176\u4ed6HOX\u901a\u8def\u9a71\u52a8\u7684\u8840\u6db2\u80bf\u7624\u3002Menin\u6291\u5236\u5242\u7684\u4f5c\u7528\u673a\u7406\u4e3a\uff1a\u7ade\u4e89\u6027\u963b\u65adMenin\u4e0eKMT2A\u86cb\u767d\u76f8\u4e92\u4f5c\u7528\uff0c\u8bf1\u5bfc\u80bf\u7624\u7ec6\u80de\u8f6c\u5f55\u91cd\u7f16\u7a0b\u3001\u542f\u52a8\u5206\u5316\uff0c\u5e76\u524a\u5f31\u767d\u8840\u75c5\u5e72\u7ec6\u80de\u5e72\u6027\u3002\u533a\u522b\u4e8e\u4f20\u7edf\u5316\u7597\u975e\u7279\u5f02\u6027\u7ec6\u80de\u6bd2\u6740\u4f24\uff0c\u8be5\u7597\u6cd5\u5c5e\u4e8e\u8f6c\u5f55\u6c34\u5e73\u7cbe\u51c6\u8c03\u63a7\uff0c\u9a71\u52a8\u6076\u6027\u7ec6\u80de \u201c\u6b63\u5e38\u5206\u5316\u201d\uff0c\u5b9e\u73b0\u9776\u5411\u5e72\u9884\u3002<\/p>\n\n\n\n

\u4e8c\u3001\u5df2\u83b7\u6279\u836f\u7269\uff1a\u53cc\u96c4\u5e76\u7acb\uff0c\u5404\u6709\u4fa7\u91cd<\/h2>\n\n\n\n

\u76ee\u524d\u5168\u7403\u5171\u6709\u4e24\u6b3eMenin\u6291\u5236\u5242\u83b7\u5f97\u7f8e\u56fdFDA\u6279\u51c6[1][4]\u3002<\/p>\n\n\n\n

1. Revuforj\u00ae\uff08revumenib\uff09\u2014\u2014Syndax Pharmaceuticals<\/h3>\n\n\n\n

\u88681. Revuforj\u00ae\uff08revumenib\uff09FDA\u83b7\u6279\u4fe1\u606f\u6c47\u603b<\/strong><\/p>\n\n\n\n

\u9879\u76ee<\/strong><\/td>\u5185\u5bb9<\/strong><\/td><\/tr>
\u9996\u6b21\u83b7\u6279<\/strong><\/td>2024\u5e7411\u670815\u65e5\uff0c\u7528\u4e8e\u643a\u5e26KMT2A\u91cd\u6392\u7684\u590d\u53d1\/\u96be\u6cbb\u6027\u6025\u6027\u767d\u8840\u75c5\uff08\u6210\u4eba\u548c\u22651\u5c81\u513f\u7ae5\uff09[1]<\/td><\/tr>
\u4e8c\u6b21\u83b7\u6279<\/strong><\/td>2025\u5e7410\u670824\u65e5\uff0c\u6269\u5c55\u81f3\u643a\u5e26NPM1\u7a81\u53d8\u7684\u590d\u53d1\/\u96be\u6cbb\u6027AML\uff08\u6210\u4eba\u548c\u22651\u5c81\u513f\u7ae5\uff09[5]<\/td><\/tr>
\u6838\u5fc3\u4f18\u52bf<\/strong><\/td>\u5168\u7403\u9996\u4e2a\u4e14\u552f\u4e00\u8986\u76d6\u513f\u7ae5\u60a3\u8005\uff08\u22651\u5c81\uff09\u7684Menin\u6291\u5236\u5242\uff0c\u4e5f\u662f\u552f\u4e00\u540c\u65f6\u8986\u76d6KMT2A\u6613\u4f4d\u548cNPM1\u7a81\u53d8\u4e24\u5927\u9002\u5e94\u75c7\u7684\u836f\u7269[5]<\/td><\/tr>
\u5173\u952e\u8bd5\u9a8c<\/strong><\/td>AUGMENT-101\u2014\u2014KMT2Ar\u961f\u5217\u4e2dCR+CRh\u7387\u4e3a21.2%\uff0822\/104\uff09\uff0c\u4e2d\u4f4d\u7f13\u89e3\u6301\u7eed\u65f6\u95f46.4\u4e2a\u6708\uff1bNPM1m\u961f\u5217\u4e2dCR+CRh\u7387\u4e3a23.1%\uff0815\/65\uff09[1][5]<\/td><\/tr>
\u5546\u4e1a\u8868\u73b0<\/strong><\/td>2026\u5e74\u7b2c\u4e00\u5b63\u5ea6\u51c0\u6536\u51654890\u4e07\u7f8e\u5143\uff0c\u540c\u6bd4\u589e\u957f144%[6]<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

\u6570\u636e\u6765\u6e90\uff1aFDA\u5b98\u65b9\u516c\u544a[1][5]\uff1bSyndax Pharmaceuticals 2026\u5e74\u7b2c\u4e00\u5b63\u5ea6\u8d22\u62a5[6]<\/em><\/p>\n\n\n\n

2. Komzifti\u00ae\uff08ziftomenib\uff09\u2014\u2014Kura Oncology<\/h3>\n\n\n\n

\u88682. Komzifti\u00ae\uff08ziftomenib\uff09FDA\u83b7\u6279\u4fe1\u606f\u6c47\u603b<\/strong><\/p>\n\n\n\n

\u9879\u76ee<\/strong><\/td>\u5185\u5bb9<\/strong><\/td><\/tr>
\u83b7\u6279\u65f6\u95f4<\/strong><\/td>2025\u5e7411\u670813\u65e5[4]<\/td><\/tr>
\u9002\u5e94\u75c7<\/strong><\/td>\u643a\u5e26NPM1\u7a81\u53d8\u7684\u590d\u53d1\/\u96be\u6cbb\u6027AML\u6210\u4eba\u60a3\u8005[4]<\/td><\/tr>
\u5173\u952e\u8bd5\u9a8c<\/strong><\/td>KOMET-001\u2014\u2014CR+CRh\u7387\u4e3a21.4%\uff0824\/112\uff09\uff0c\u4e2d\u4f4d\u7f13\u89e3\u6301\u7eed\u65f6\u95f45.0\u4e2a\u6708[4]<\/td><\/tr>
\u5dee\u5f02\u5316<\/strong><\/td>\u76ee\u524d\u4ec5\u8986\u76d6NPM1\u7a81\u53d8\u5355\u4e00\u4e9a\u578b\uff0c\u6682\u672a\u83b7\u6279\u513f\u7ae5\u9002\u5e94\u75c7\u53caKMT2A\u91cd\u6392\u9002\u5e94\u75c7\uff0c\u4f46\u9776\u5411\u9009\u62e9\u6027\u66f4\u9ad8\uff1bFDA\u6279\u51c6\u65f6\u672a\u5305\u542bQTc\u5ef6\u957f\u7684\u9ed1\u6846\u8b66\u544a[4]<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

\u6570\u636e\u6765\u6e90\uff1aFDA\u5b98\u65b9\u516c\u544a[4]\uff1bKura Oncology\u65b0\u95fb\u7a3f<\/em><\/p>\n\n\n\n

\u4e09\u3001\u5b89\u5168\u6027\uff1a\u5206\u5316\u7efc\u5408\u5f81\u4e0eQTc\u95f4\u671f\u5ef6\u957f<\/h2>\n\n\n\n

Menin\u6291\u5236\u5242\u5c5e\u4e8e\u65b0\u578b\u5206\u5316\u8bf1\u5bfc\u7c7b\u9776\u5411\u836f\u7269\uff0c\u5176\u4e0d\u826f\u53cd\u5e94\u8c31\u4e0e\u4f20\u7edf\u5316\u7597\u5b8c\u5168\u4e0d\u540c\uff0c\u6bd2\u6027\u7279\u5f81\u4e0e\u5176\u72ec\u7279\u7684\u4f5c\u7528\u673a\u5236\u9ad8\u5ea6\u7ed1\u5b9a[1][4]\u3002<\/p>\n\n\n\n

\u5206\u5316\u7efc\u5408\u5f81\uff08Differentiation Syndrome\uff09<\/h3>\n\n\n\n

\u5206\u5316\u7efc\u5408\u5f81\u662fMenin\u6291\u5236\u5242\u6700\u5177\u4ee3\u8868\u6027\u7684\u201c\u7c7b\u6548\u5e94\u6bd2\u6027\u201d\uff0c\u5e76\u975e\u836f\u7269\u76f4\u63a5\u635f\u4f24\uff0c\u800c\u662f\u836f\u7269\u8d77\u6548\u7684\u7279\u5f81\u6027\u8868\u73b0\u3002\u836f\u7269\u8bf1\u5bfc\u5927\u91cf\u505c\u6ede\u5206\u5316\u7684\u767d\u8840\u75c5\u7ec6\u80de\u5feb\u901f\u6210\u719f\uff0c\u91ca\u653e\u708e\u75c7\u56e0\u5b50\u3001\u6fc0\u6d3b\u5185\u76ae\u53cd\u5e94\uff0c\u5f15\u53d1\u6bdb\u7ec6\u8840\u7ba1\u6e17\u6f0f\u3001\u6c34\u80bf\u3001\u4f4e\u6c27\u3001\u80ba\u90e8\u6d78\u6da6\u7b49\u7cfb\u5217\u4e34\u5e8a\u75c7\u72b6\u3002<\/p>\n\n\n\n

\u4e0d\u540cMenin\u6291\u5236\u5242\u7684\u22653\u7ea7\u5206\u5316\u7efc\u5408\u5f81\u53d1\u751f\u7387\u6574\u4f53\u53ef\u63a7\uff1arevumenib\u7ea616%[1]\uff0cziftomenib\u7ea614%[4]\uff0cbleximenib\u5355\u836f\u7ea67%\uff088\/121\u60a3\u8005\uff0c\u542b2\u4f8b\u81f4\u6b7b\u4e8b\u4ef6\uff09[7]\u3002\u4e0eAPL\u7ef4A\u9178\u8bf1\u5bfc\u5206\u5316\u7efc\u5408\u5f81\u7ba1\u7406\u539f\u5219\u4e00\u81f4\uff0c\u4e34\u5e8a\u4ee5\u201c\u65e9\u671f\u7cd6\u76ae\u8d28\u6fc0\u7d20\u5e72\u9884\u4e3a\u6838\u5fc3\uff0c\u65e0\u9700\u76f2\u76ee\u505c\u836f\uff0c\u6574\u4f53\u53ef\u9632\u53ef\u63a7\u3002<\/p>\n\n\n\n

QTc\u95f4\u671f\u5ef6\u957f<\/h3>\n\n\n\n

QTc\u95f4\u671f\u5ef6\u957f\u662fMenin\u6291\u5236\u5242\u9700\u91cd\u70b9\u76d1\u6d4b\u7684\u5fc3\u810f\u5b89\u5168\u98ce\u9669\u3002\u5176\u4e2d\uff0cRevumenib\u56e0\u660e\u786e\u5fc3\u810f\u7535\u751f\u7406\u5f71\u54cd\uff0cFDA\u8bf4\u660e\u4e66\u5305\u542b\u5206\u5316\u7efc\u5408\u5f81\u7684\u9ed1\u6846\u8b66\u544a\uff0cQTc\u95f4\u671f\u5ef6\u957f\u5217\u4e8e\u8b66\u544a\u4e0e\u6ce8\u610f\u4e8b\u9879\u4e2d\uff0c\u8981\u6c42\u6cbb\u7597\u524d\u540e\u89c4\u8303\u76d1\u6d4b\u5fc3\u7535\u56fe\u53ca\u7535\u89e3\u8d28\u6c34\u5e73[1]\u3002<\/p>\n\n\n\n

\u503c\u5f97\u6ce8\u610f\u7684\u662f\uff0c\u8be5\u6bd2\u6027\u5b58\u5728\u663e\u8457\u836f\u7269\u5f02\u8d28\u6027\uff1aziftomenib\u83b7\u6279\u8bf4\u660e\u4e66\u65e0QTc\u5ef6\u957f\u9ed1\u6846\u8b66\u544a[4]\uff0cbleximenib\u4e34\u5e8a\u8bd5\u9a8c\u4ea6\u672a\u89c2\u5bdf\u5230\u660e\u786e\u5fc3\u810fQTc\u5ef6\u957f\u4fe1\u53f7[7] \uff0c\u63d0\u793a\u4e0d\u540c\u7ed3\u6784Menin\u6291\u5236\u5242\u7684\u5fc3\u810f\u5b89\u5168\u8c31\u5b58\u5728\u5dee\u5f02\u3002<\/p>\n\n\n\n

\u5176\u4ed6\u5e38\u89c1\u4e0d\u826f\u53cd\u5e94<\/h3>\n\n\n\n

\u809d\u529f\u80fd\u6307\u6807\u5f02\u5e38\uff08AST\/ALT\u5347\u9ad8\uff09\u3001\u80c3\u80a0\u9053\u53cd\u5e94\uff08\u6076\u5fc3\u3001\u5455\u5410\uff09\u3001\u53d1\u70ed\u6027\u4e2d\u6027\u7c92\u7ec6\u80de\u51cf\u5c11\u7b49\uff0c\u901a\u5e38\u5728\u8054\u5408\u7528\u836f\u4e2d\u53ef\u63a7[1][4]\u3002<\/p>\n\n\n\n

\u56db\u3001\u524d\u7ebf\u7a81\u7834\uff1a\u4ece\u540e\u7ebf\u633d\u6551\u8d70\u5411\u4e00\u7ebf\u6cbb\u7597<\/h2>\n\n\n\n

\u65e2\u5f80Menin\u6291\u5236\u5242\u4ec5\u7528\u4e8e\u590d\u53d1\u96be\u6cbb\u6025\u6027\u767d\u8840\u75c5\u7684\u540e\u7ebf\u633d\u6551\u6cbb\u7597\u3002\u800c2026\u5e74EHA\u5e74\u4f1a\u516c\u5e03\u7684\u591a\u9879\u524d\u77bb\u6027\u7814\u7a76\u6570\u636e\uff0c\u6b63\u5f0f\u5c06Menin\u6291\u5236\u5242\u7684\u5e94\u7528\u573a\u666f\u4ece\u4f20\u7edf\u540e\u7ebf\u515c\u5e95\u6cbb\u7597\uff0c\u62d3\u5c55\u81f3\u201c\u521d\u8bca\u9ad8\u5371\u60a3\u8005\u7684\u4e00\u7ebf\u8054\u5408\u6cbb\u7597\u3001\u79fb\u690d\u540e\u7ef4\u6301\u6cbb\u7597\u201d\u5168\u65b0\u9886\u57df\uff0c\u6807\u5fd7\u7740\u8be5\u7c7b\u9776\u5411\u836f\u7269\u6b63\u5f0f\u8fdb\u5165\u524d\u7ebf\u6cbb\u7597\u65f6\u4ee3[8][9]\u3002<\/p>\n\n\n\n

\uff08\u4e00\uff09Ziftomenib + 7+3\u5316\u7597\uff08KOMET-007\uff0cEHA 2026\uff09<\/h3>\n\n\n\n

\u572899\u540d\u65b0\u8bca\u65ad\u7684NPM1\u7a81\u53d8\u6216KMT2A\u91cd\u6392AML\u60a3\u8005\u4e2d\uff08ziftomenib 600mg\u6bcf\u65e5\u4e00\u6b21\u8054\u5408\u6807\u51c67+3\u8bf1\u5bfc\u5316\u7597\uff09[8]\uff1a<\/p>\n\n\n\n

\u88683. KOMET-007\u8bd5\u9a8cEHA 2026\u66f4\u65b0\u6570\u636e<\/strong><\/p>\n\n\n\n

\u6307\u6807<\/strong><\/td>NPM1<\/strong>\u7a81\u53d8\u961f\u5217\uff08n=49\uff09<\/strong><\/td>KMT2A<\/strong>\u91cd\u6392\u961f\u5217\uff08n=50\uff09<\/strong><\/td><\/tr>
\u590d\u5408\u5b8c\u5168\u7f13\u89e3\u7387\uff08CRc\uff09<\/strong><\/td>96%\uff0847\/49\uff09<\/td>90%\uff0845\/50\uff09<\/td><\/tr>
MRD<\/strong>\u9634\u6027\u7387\uff08CRc\u5e94\u7b54\u8005\uff09<\/strong><\/td>83%\uff0839\/47\uff09<\/td>82%\uff0832\/39\uff09<\/td><\/tr>
\u4e2d\u4f4d\u968f\u8bbf\u65f6\u95f4<\/strong><\/td>14.9\u4e2a\u6708<\/td>9.3\u4e2a\u6708<\/td><\/tr>
1<\/strong>\u5e74\u603b\u751f\u5b58\u7387<\/strong><\/td>94%<\/td>70%<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

\u6570\u636e\u6765\u6e90\uff1aKOMET-007\u8bd5\u9a8cEHA 2026\u66f4\u65b0[8]\uff1bKura Oncology\u65b0\u95fb\u7a3f\uff082026\u5e746\u670811\u65e5\uff09<\/em><\/p>\n\n\n\n

\u8fd9\u4e9b\u6570\u636e\u663e\u8457\u8d85\u8d8a\u5386\u53f27+3\u5316\u7597\u7684\u7597\u6548\u57fa\u51c6\u3002\u57fa\u4e8e\u6b64\uff0cKOMET-017 III\u671f\u968f\u673a\u5bf9\u7167\u7814\u7a76\u5df2\u5168\u9762\u542f\u52a8[8]\u3002<\/p>\n\n\n\n

\uff08\u4e8c\uff09Revumenib + \u5f3a\u5316\u7597\uff08SNDX-5613-0708\uff0cEHA 2026\uff09<\/h3>\n\n\n\n

\u5728\u65b0\u8bca\u65ad\u7684NPM1\u7a81\u53d8\u6216KMT2A\u91cd\u6392AML\u60a3\u8005\u4e2d\uff0crevumenib\u8054\u5408\u5f3a\u5316\u7597\u53d6\u5f97\u4e8697%\uff0834\/35\uff09\u7684\u590d\u5408\u5b8c\u5168\u7f13\u89e3\u7387\u548c77%\uff0827\/35\uff09\u7684\u5b8c\u5168\u7f13\u89e3\u7387[9]\u3002MRD\u9634\u6027\u7387\u5728CRc\u60a3\u8005\u4e2d\u4e3a86%\uff0825\/29\uff09\uff0c\u5728CR\u60a3\u8005\u4e2d\u4e3a87%\uff0820\/23\uff09\u3002\u5b89\u5168\u6027\u65b9\u9762\uff0c\u65e03\u7ea7\u4ee5\u4e0a\u5206\u5316\u7efc\u5408\u5f81\u6216QTc\u5ef6\u957f\u4e8b\u4ef6[9]\u3002<\/p>\n\n\n\n

\u4e94\u3001\u79fb\u690d\u540e\u7ef4\u6301\u6cbb\u7597\uff1a2\u5e74OS\u7387\u8fbe90%<\/h2>\n\n\n\n

2026\u5e74ASCO\u5e74\u4f1a\u4e0a\u516c\u5e03\u7684\u4e00\u9879\u5173\u952e\u6c47\u603b\u5206\u6790\uff0c\u63ed\u793a\u4e86Menin\u6291\u5236\u5242\u5728\u79fb\u690d\u540e\u7ef4\u6301\u6cbb\u7597\u4e2d\u7684\u5de8\u5927\u6f5c\u529b[10]\u3002<\/p>\n\n\n\n

\u88684. Revumenib\u79fb\u690d\u540e\u7ef4\u6301\u6cbb\u7597\u6570\u636e\uff08ASCO 2026\uff09<\/strong><\/p>\n\n\n\n

\u6307\u6807<\/strong><\/td>\u6570\u636e<\/strong><\/td><\/tr>
\u60a3\u8005\u6570\u91cf<\/strong><\/td>24\u540d\uff0813\u540d\u6210\u4eba\uff0c11\u540d\u513f\u7ae5\uff09<\/td><\/tr>
\u57fa\u56e0\u578b\u5206\u5e03<\/strong><\/td>71% KMT2A\u91cd\u6392\uff0c25% NPM1\u7a81\u53d8\uff0c4% NUP98\u91cd\u6392<\/td><\/tr>
\u4e2d\u4f4d\u5e74\u9f84<\/strong><\/td>22\u5c81\uff08\u8303\u56f41-74\u5c81\uff09<\/td><\/tr>
2<\/strong>\u5e74\u603b\u751f\u5b58\uff08OS\uff09\u7387<\/strong><\/td>90%\uff08\u5386\u53f2\u540c\u7c7b\u57fa\u56e0\u578b\u5bf9\u7167\u7ec4\u4ec5\u4e3a51%\uff09<\/td><\/tr>
\u4e2d\u4f4d\u968f\u8bbf<\/strong><\/td>21\u4e2a\u6708\uff1b\u4e2d\u4f4dOS\u548c\u65e0\u4e8b\u4ef6\u751f\u5b58\u671f\u5747\u672a\u8fbe\u5230<\/td><\/tr>
\u79fb\u690d\u540e1\u5e74\u7d2f\u8ba1\u590d\u53d1\u7387<\/strong><\/td>CR1\u60a3\u8005\u4e3a0%\uff0cCR2+\u60a3\u8005\u4e3a17%<\/td><\/tr>
\u4e3b\u8981\u4e0d\u826f\u53cd\u5e94<\/strong><\/td>\u8840\u5c0f\u677f\u51cf\u5c11\uff0883%\uff09\uff0c\u901a\u8fc7\u5242\u91cf\u8c03\u6574\u53ef\u7ba1\u7406<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

\u6570\u636e\u6765\u6e90\uff1aASCO 2026\u53e3\u5934\u62a5\u544a\uff08\u6458\u8981\u53f76505\uff09[10]\uff1bSyndax Pharmaceuticals\u65b0\u95fb\u7a3f\uff082026\u5e746\u67082\u65e5\uff09<\/em><\/p>\n\n\n\n

\u8fd9\u4e00\u6570\u636e\u4f7frevumenib\u6210\u4e3a\u79fb\u690d\u540e\u7ef4\u6301\u6cbb\u7597\u7684\u6709\u529b\u5019\u9009\u3002\u9996\u4e2a\u968f\u673a\u3001\u5b89\u6170\u5242\u5bf9\u7167\u7684\u79fb\u690d\u540e\u7ef4\u6301\u8bd5\u9a8cMenTain\u7814\u7a76\u5df2\u8ba1\u5212\u542f\u52a8[10]\u3002<\/p>\n\n\n\n

\u516d\u3001SAVE\u4e09\u8054\u65b9\u6848\uff1a\u7834\u89e3\u8010\u836f\u56f0\u5c40<\/h2>\n\n\n\n

\u5728EHA 2026\u4e0a\u516c\u5e03\u7684SAVE\u8bd5\u9a8c\uff08revumenib + \u5730\u897f\u4ed6\u6ee8\/\u897f\u8fbe\u5c3f\u82f7 + \u7ef4\u5948\u514b\u62c9\uff09\u4e2d[11]\uff1a<\/p>\n\n\n\n

\u88685. SAVE\u8bd5\u9a8c\u5173\u952e\u6570\u636e\uff08EHA 2026 \/ JCO\u53d1\u8868\uff09<\/strong><\/p>\n\n\n\n

\u6307\u6807<\/strong><\/td>\u6570\u636e<\/strong><\/td><\/tr>
\u5165\u7ec4\u60a3\u8005\u6570<\/strong><\/td>42\u540d\uff08\u4e2d\u4f4d\u5e74\u9f8440\u5c81\uff0c\u8303\u56f412-82\u5c81\uff09<\/td><\/tr>
\u603b\u4f53\u53cd\u5e94\u7387\uff08ORR\uff09<\/strong><\/td>88%\uff0837\/42\uff09<\/td><\/tr>
\u590d\u5408\u5b8c\u5168\u7f13\u89e3\uff08CRc\uff09\u7387<\/strong><\/td>71%\uff0830\/42\uff09<\/td><\/tr>
CR\/CRh<\/strong>\u7387<\/strong><\/td>60%\uff0825\/42\uff09<\/td><\/tr>
MRD<\/strong>\u9634\u6027\u7387<\/strong><\/td>80%\uff0824\/30\uff09\u7684\u53ef\u8bc4\u4f30CRc\u5e94\u7b54\u8005\u8fbe\u5230MRD\u9634\u6027<\/td><\/tr>
\u6865\u63a5\u79fb\u690d\u7387<\/strong><\/td>45%\uff0819\/42\uff09<\/td><\/tr>
\u7ef4\u5948\u514b\u62c9\u7ecf\u6cbb\u60a3\u8005CR\/CRh\u7387<\/strong><\/td>50%\uff0811\/22\uff09<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

\u6570\u636e\u6765\u6e90\uff1aSAVE\u8bd5\u9a8cEHA 2026\uff1b\u53d1\u8868\u4e8e\u300aJournal of Clinical Oncology\u300b[11]\uff082026\u5e746\u670811\u65e5\uff09<\/em><\/p>\n\n\n\n

\u8be5\u65b9\u6848\u5728\u65e2\u5f80\u7ef4\u5948\u514b\u62c9\u8010\u836f\u7684\u6781\u96be\u6cbb\u60a3\u8005\u4e2d\u4ecd\u663e\u793a\u51fa\u663e\u8457\u7597\u6548\u3002\u5728\u7ef4\u5948\u514b\u62c9\u7ecf\u6cbb\u60a3\u8005\u4e2d\uff0cCR\/CRh\u7387\u8fbe50%\uff0c\u4e2d\u4f4d\u603b\u751f\u5b58\u671f\u7ea612\u4e2a\u6708\uff0c\u800c\u5386\u53f2\u57fa\u51c6\u4e0d\u8db33\u4e2a\u6708[11]\u3002<\/p>\n\n\n\n

\u4e03\u3001\u8010\u836f\u673a\u5236\u4e0e\u5e94\u5bf9\u7b56\u7565\uff1a\u4e0b\u4e00\u4ee3\u7ade\u4e89\u7684\u6838\u5fc3\u6218\u573a<\/h2>\n\n\n\n

\u968f\u7740Menin\u6291\u5236\u5242\u4e34\u5e8a\u5e94\u7528\u4e0d\u65ad\u63a8\u8fdb\uff0c\u6cbb\u7597\u540e\u51fa\u73b0\u7684\u83b7\u5f97\u6027\u8010\u836f\u5df2\u6210\u4e3a\u9650\u5236\u957f\u671f\u6cbb\u7597\u7684\u5173\u952e\u74f6\u9888[12]\u3002<\/p>\n\n\n\n

\uff08\u4e00\uff09MEN1<\/em>\u57fa\u56e0\u7a81\u53d8\u662f\u6700\u6838\u5fc3\u7684\u8010\u836f\u673a\u5236<\/h3>\n\n\n\n

\u57fa\u4e8eCRISPR\u78b1\u57fa\u7f16\u8f91\u9ad8\u901a\u91cf\u7b5b\u9009\uff0c\u5df2\u7cfb\u7edf\u7ed8\u5236\u4e86\u53ef\u4ecb\u5bfc\u591a\u79cdMenin\u6291\u5236\u5242\u4ea4\u53c9\u8010\u836f\u7684MEN1<\/em>\u7a81\u53d8\u56fe\u8c31[12][13]\u3002\u4e34\u5e8a\u68c0\u51fa\u7684\u8010\u836f\u7a81\u53d8\u96c6\u4e2d\u4e8e Menin \u86cb\u767d KMT2A \u7ed3\u5408\u53e3\u888b\uff0c\u5305\u62ecM327I\/V\/T\u3001G331R\/D\u3001T349M\u7b49\u4f4d\u70b9\u3002\u4e34\u5e8a\u6570\u636e\u663e\u793a\uff0c\u7ecfrevumenib\u5355\u836f\u6cbb\u7597\u8fdb\u5c55\u7684\u60a3\u8005\u4e2d\uff0c\u91c7\u7528\u9ad8\u7075\u654f\u5ea6 ddPCR \u68c0\u6d4b\uff0cMEN1<\/em>\u8010\u836f\u7a81\u53d8\u68c0\u51fa\u7387\u63a5\u8fd140%[12]\u3002<\/p>\n\n\n\n

\u5173\u952e\u7279\u5f81<\/strong>\uff1a\u4e0d\u540c\u5316\u5b66\u7ed3\u6784\u7684 Menin\u6291\u5236\u5242\u5bf9\u7279\u5b9aMEN1<\/em>\u7a81\u53d8\u4f53\u5b58\u5728\u5dee\u5f02\u5316\u6d3b\u6027\u3002\u4f8b\u5982\uff0cziftomenib\u5bf9revumenib\u8010\u836f\u76f8\u5173T349M\u3001G331R\u7a81\u53d8\u4ecd\u5177\u5907\u6291\u5236\u6d3b\u6027\uff1bbleximenib\u53ef\u7ef4\u6301\u5bf9<\/a><\/a>MEN1^<\/sup>M327I^<\/sup><\/a>[xg1]<\/a> <\/sup>\u7a81\u53d8\u86cb\u767d\u7684\u7ed3\u5408\u4eb2\u548c\u529b [13][14]\uff0c\u4e3a\u8010\u836f\u540e\u836f\u7269\u5e8f\u8d2f\u65b9\u6848\u5960\u5b9a\u4e86\u7406\u8bba\u57fa\u7840\u3002<\/p>\n\n\n\n

\uff08\u4e8c\uff09\u5e8f\u8d2f\u6cbb\u7597\u5df2\u83b7\u5f97\u521d\u6b65\u4e34\u5e8a\u9a8c\u8bc1<\/h3>\n\n\n\n

2026\u5e74\u300aLeukemia\u300b\u62a5\u9053\u6982\u5ff5\u9a8c\u8bc1\u6848\u4f8b\uff1a\u60a3\u8005\u68c0\u51faMEN1^<\/sup>M327I^<\/sup><\/a>[xg2]<\/a> <\/sup>\u7a81\u53d8\u540e\uff0c\u7531revumenib\u6362\u7528bleximenib\uff0c\u8010\u836f\u7a81\u53d8\u4e30\u5ea6\u753129.8%\u964d\u81f30%[14]\u3002<\/p>\n\n\n\n

\u53e6\u6709\u7814\u7a76\u663e\u793a\uff0c\u591a\u7ebf\u6cbb\u7597\u60a3\u8005\u5bf9\u4e00\u79cd Menin \u6291\u5236\u5242\u8010\u836f\u540e\uff0c\u4ecd\u6709\u53ef\u80fd\u4ece\u53e6\u4e00\u6b3e\u540c\u9776\u70b9\u836f\u7269\u83b7\u76ca\uff0c\u80bf\u7624\u7ec6\u80de\u4f9d\u65e7\u4f9d\u8d56 Menin-KMT2A \u81f4\u764c\u901a\u8def[15]\u3002<\/p>\n\n\n\n

\uff08\u4e09\uff09\u8010\u836f\u7a81\u53d8\u7684\u52a8\u6001\u76d1\u6d4b<\/h3>\n\n\n\n

cfDNA-NGS \u68c0\u6d4b\u5e73\u53f0\uff08\u5982 MSK-ACCESS\uff09\u53ef\u65e0\u521b\u3001\u6301\u7eed\u76d1\u6d4bMEN1<\/em>\u8010\u836f\u7a81\u53d8\u3002\u63a8\u52a8\u524d\u77bb\u6027\u8fde\u7eed\u5206\u5b50\u76d1\u6d4b\uff0c\u6709\u52a9\u4e8e\u65e9\u671f\u9884\u5224\u8010\u836f\u3001\u5b8c\u5584\u7a81\u53d8\u8c31\u7279\u5f81[14-15]\u3002<\/p>\n\n\n\n

\uff08\u56db\uff09\u8054\u5408\u65b9\u6848\u9884\u9632\/\u9006\u8f6c\u8010\u836f<\/h3>\n\n\n\n

\u9664\u836f\u7269\u5e8f\u8d2f\u7b56\u7565\uff0c\u5f53\u524d\u7814\u7a76\u8fd8\u805a\u7126\u4e8eMenin\u6291\u5236\u5242\u4e0eBET\u6291\u5236\u5242\u3001BRG1\/BRM\u6291\u5236\u5242\u7b49\u8054\u5408\u65b9\u6848\u4ee5\u514b\u670d\u6216\u9884\u9632\u8010\u836f\u3002\u6b64\u5916\uff0cMenin\u6291\u5236\u5242\u53ef\u63d0\u5347\u767d\u8840\u75c5\u514d\u75ab\u539f\u6027\u3001\u589e\u5f3aT\u7ec6\u80de\u6740\u4f24\u529f\u80fd\uff0c\u4e3a\u514d\u75ab\u8054\u5408\u65b9\u6848\u63d0\u4f9b\u65b0\u601d\u8def\u3002<\/p>\n\n\n\n

\u516b\u3001\u5728\u7814\u7ba1\u7ebf\uff1a\u4e0b\u4e00\u4ee3\u7ade\u4e89\u52a0\u901f<\/h2>\n\n\n\n

\u76ee\u524d\u81f3\u5c11\u67095\u6b3e\u4ee5\u4e0aMenin\u6291\u5236\u5242\u5904\u4e8e\u4e34\u5e8a\u5f00\u53d1\u9636\u6bb5\uff1a<\/p>\n\n\n\n

\u88686. \u5728\u7814Menin\u6291\u5236\u5242\u7ba1\u7ebf\u4e00\u89c8<\/strong><\/p>\n\n\n\n

\u836f\u7269<\/strong><\/td>\u7814\u53d1\u673a\u6784<\/strong><\/td>\u9636\u6bb5<\/strong><\/td>\u7279\u70b9<\/strong><\/td><\/tr>
Bleximenib<\/strong>\uff08JNJ-75276617\uff09<\/strong><\/td>\u5f3a\u751f<\/td>I\/II\/III\u671f<\/td>\u5206\u5316\u7efc\u5408\u5f81\u53d1\u751f\u7387\u8f83\u4f4e\uff08\u5355\u836f7%\uff0c\u8054\u54084%\uff09\uff1b\u65e0QTc\u5ef6\u957f\u4fe1\u53f7[7]<\/td><\/tr>
Enzomenib<\/strong>\uff08DSP-5336\uff09<\/strong><\/td>\u4f4f\u53cb\u5236\u836f<\/td>I\/II\u671f<\/td>FDA\u5feb\u901f\u901a\u9053\u8ba4\u5b9a\uff0c\u65e0QTc\u5ef6\u957f\u4fe1\u53f7[16]<\/td><\/tr>
Icovamenib<\/strong>\uff08BMF-219\uff09<\/strong><\/td>Biomea Fusion<\/td>II\u671f<\/td>\u63a2\u7d22\u7cd6\u5c3f\u75c5\u7b49\u975e\u80bf\u7624\u9002\u5e94\u75c7[17]<\/td><\/tr>
HMPL-506<\/strong><\/td>\u548c\u9ec4\u533b\u836f<\/td>I\u671f<\/td>\u4e2d\u56fdI\u671f\u5df2\u542f\u52a8\uff0c\u9488\u5bf9KMT2A\u91cd\u6392\u548c\/\u6216NPM1\u7a81\u53d8\u7684R\/R\u8840\u6db2\u6076\u6027\u80bf\u7624[18]<\/td><\/tr>
BN-104<\/strong><\/td>\u767e\u6069\u8bfa\/\u56fd\u5185\u4f01\u4e1a<\/td>I\/II\u671f<\/td>NMPA\u7a81\u7834\u6027\u6cbb\u7597\u54c1\u79cd\uff0c\u672a\u51fa\u73b0\u22653\u7ea7QTc\u6216\u5206\u5316\u7efc\u5408\u5f81<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

\u6570\u636e\u6765\u6e90\uff1a\u5404\u4f01\u4e1a\u516c\u5f00\u4fe1\u606f\u53caClinicalTrials.gov[7][16][17][18]<\/em><\/p>\n\n\n\n

\u4e2d\u56fd\u7ba1\u7ebf\u65b9\u9762\uff0c\u548c\u9ec4\u533b\u836f\u7684HMPL-506\u4e2d\u56fdI\u671f\u4e34\u5e8a\u8bd5\u9a8c\u5df2\u4e8e2024\u5e745\u670831\u65e5\u5b8c\u6210\u9996\u4f8b\u7ed9\u836f\uff0c\u9488\u5bf9KMT2A\u91cd\u6392\u548c\/\u6216NPM1\u7a81\u53d8\u7684\u590d\u53d1\/\u96be\u6cbb\u6027\u8840\u6db2\u6076\u6027\u80bf\u7624\uff08NCT06387082\uff09[18]\u3002<\/p>\n\n\n\n

\u4e5d\u3001\u603b\u7ed3\uff1aMenin\u6291\u5236\u5242\u65f6\u4ee3\u7684\u4e09\u4e2a\u5173\u952e\u8bcd<\/h2>\n\n\n\n

1. \u524d\u7ebf\u5316<\/h3>\n\n\n\n

EHA 2026\u6570\u636e\u8bc1\u660e\uff0cMenin\u6291\u5236\u5242\u8054\u5408\u5316\u7597\u5728\u4e00\u7ebf\u6cbb\u7597\u4e2d\u53ef\u5b9e\u73b090%\u4ee5\u4e0a\u7684CRc\u7387\uff0c\u663e\u8457\u8d85\u8d8a\u5386\u53f2\u57fa\u51c6[8][9]\u3002\u5168\u7403\u591a\u4e2aIII\u671f\u8bd5\u9a8c\uff08KOMET-017\u7b49\uff09\u6b63\u5728\u52a0\u901f\u63a8\u8fdb\u3002<\/p>\n\n\n\n

2. \u5168\u7a0b\u5316<\/h3>\n\n\n\n

\u4ece\u540e\u7ebf\u633d\u6551\u2192\u4e00\u7ebf\u8054\u5408\u2192\u79fb\u690d\u540e\u7ef4\u6301\uff0cMenin\u6291\u5236\u5242\u6b63\u5728\u8986\u76d6\u767d\u8840\u75c5\u6cbb\u7597\u7684\u5168\u94fe\u6761\u3002\u79fb\u690d\u540e2\u5e74OS\u7387\u8fbe90%\u7684\u6570\u636e\uff0c\u4f7f\u5176\u6210\u4e3a\u79fb\u690d\u540e\u7ef4\u6301\u6cbb\u7597\u7684\u6709\u529b\u5019\u9009[10]\u3002<\/p>\n\n\n\n

3. \u5dee\u5f02\u5316<\/h3>\n\n\n\n

\u968f\u7740\u66f4\u591a\u4e0b\u4e00\u4ee3\u5206\u5b50\u8fdb\u5165\u4e34\u5e8a\uff0c\u7ade\u4e89\u7126\u70b9\u6b63\u4ece”\u80fd\u5426\u6291\u5236Menin”\u8f6c\u5411”\u80fd\u5426\u514b\u670dMEN1\u8010\u836f\u7a81\u53d8”[12][13][14]\u3001”\u80fd\u5426\u62d3\u5c55\u65b0\u9002\u5e94\u75c7”\uff08NUP98\u91cd\u6392\u3001\u5b9e\u4f53\u7624\u7b49\uff09\u3001”\u80fd\u5426\u4f18\u5316\u5b89\u5168\u6027”\uff08QTc\u3001\u5206\u5316\u7efc\u5408\u5f81\u7ba1\u7406\uff09\u3002<\/p>\n\n\n\n

\u53c2\u8003\u6587\u732e<\/h1>\n\n\n\n

[1] <\/strong>FDA. FDA approves revumenib for relapsed or refractory acute leukemia with a KMT2A translocation. FDA.gov. November 15, 2024. Available at: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-revumenib-relapsed-or-refractory-acute-leukemia-kmt2a-translocation<\/p>\n\n\n\n

[2] <\/strong>Syndax Showcases Revuforj\u00ae (revumenib) Clinical Activity in Multiple Acute Leukemia Subtypes and Settings at EHA 2026. Syndax Pharmaceuticals. June 2026. Nasdaq press release.<\/p>\n\n\n\n

[3] <\/strong>Perner F, et al. MEN1 mutations mediate clinical resistance to menin inhibition. Nature. 2023;615:913-919.<\/p>\n\n\n\n

[4] <\/strong>FDA. FDA approves ziftomenib for relapsed or refractory acute myeloid leukemia with a NPM1 mutation. FDA.gov. November 13, 2025. Available at: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-ziftomenib-relapsed-or-refractory-acute-myeloid-leukemia-npm1-mutation<\/p>\n\n\n\n

[5] <\/strong>FDA. FDA approves revumenib for relapsed or refractory acute myeloid leukemia with a susceptible NPM1 mutation. FDA.gov. October 24, 2025. Available at: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-revumenib-relapsed-or-refractory-acute-myeloid-leukemia-susceptible-npm1-mutation<\/p>\n\n\n\n

[6] <\/strong>Syndax Reports First Quarter 2026 Financial Results and Provides Business Update. Syndax Pharmaceuticals. April 30, 2026.<\/p>\n\n\n\n

[7] <\/strong>Jabbour E, et al. AML-412: Bleximenib Dose Optimization and Determination of the Recommended Phase 2 Dose (RP2D) From a Phase 1 Study in Patients With Relapsed\/Refractory Acute Leukemia (AL) With KMT2A and NPM1 Alterations. J Clin Oncol. 2025 (ASH 2024 data); Johnson & Johnson press release, June 12, 2025.<\/p>\n\n\n\n

[8] <\/strong>Kura Oncology and Kyowa Kirin to Present Updated Frontline Ziftomenib \/ 7+3 Combination Data at EHA 2026 Congress. Kura Oncology. May 13, 2026 \/ June 11, 2026.<\/p>\n\n\n\n

[9] <\/strong>Aldoss I, et al. Revumenib + intensive chemotherapy for newly diagnosed acute myeloid leukemia harboring genetic alterations in KMT2A, NPM1, or NUP98: updated phase 1 results from SNDX-5613-0708. EHA 2026. Abstract PF489.<\/p>\n\n\n\n

[10] <\/strong>Goulart H, et al. Revumenib as maintenance for AML following allogeneic stem cell transplantation. ASCO 2026. Abstract 6505.<\/p>\n\n\n\n

[11] <\/strong>Issa GC, et al. All-Oral Combination of Revumenib, Decitabine, and Venetoclax for Relapsed or Refractory AML (SAVE). Journal of Clinical Oncology. Published June 11, 2026. (EHA 2026 simultaneous presentation)<\/p>\n\n\n\n

[12] <\/strong>Perner F, et al. MEN1 mutations mediate clinical resistance to menin inhibition. Nature. 2023;615:913-919; CRISPR base editor screening: Nature Communications. 2026.<\/p>\n\n\n\n

[13] <\/strong>Bourgeois W, et al. Discerning the Landscape of Menin Inhibitor Resistance. Blood. 2024;144:724.<\/p>\n\n\n\n

[14] <\/strong>Chin KK, et al. Overcoming MEN1-mediated resistance with menin inhibitor switching in KMT2A-rearranged acute myeloid leukemia. Leukemia. 2026;40:1331-1334.<\/p>\n\n\n\n

[15] <\/strong>Markosian C, et al. The case for prospective MEN1 surveillance in the era of sequential menin inhibitor therapy. Leukemia. 2026.<\/p>\n\n\n\n

[16] <\/strong>FDA Grants Fast Track Designation to DSP-5336 in KMT2A\/NPM1+ AML. OncLive. July 15, 2024. Sumitomo Pharma press release.<\/p>\n\n\n\n

[17] <\/strong>Biomea Fusion. COVALENT-211, COVALENT-212 clinical trials. ClinicalTrials.gov. 2026.[18] <\/strong>HUTCHMED Initiates Phase I Trial of Menin Inhibitor HMPL-506 in Patients with Hematological Malignancies in China. HUTCHMED. June 7, 2024. NCT06387082.<\/p>\n\n\n\n

[18] <\/strong>HUTCHMED Initiates Phase I Trial of Menin Inhibitor HMPL-506 in Patients with Hematological Malignancies in China. HUTCHMED. June 7, 2024. NCT06387082.<\/p>\n\n\n\n

\n\n\n\n

<\/a><\/p>\n\n\n\n

\u64b0\u7a3f\uff1a\u90d1\u53f6\u654f<\/p>\n\n\n\n

\u5ba1\u6838\uff1a\u5bab\u96ea<\/p>\n","protected":false},"excerpt":{"rendered":"

2024\u5e7411\u670815\u65e5\uff0c\u7f8e\u56fdFDA\u6279\u51c6\u5168\u7403\u9996\u6b3eMenin\u6291\u5236\u5242Revuforj\u00ae\uff08revumenib\uff09\uff0c\u7528\u4e8e\u6cbb\u7597\u643a\u5e26KMT2A\u91cd\u6392\u7684\u590d\u53d1\/\u96be\u6cbb\u6027\u6025\u6027\u767d\u8840\u75c5[1]\u3002\u81ea\u9996\u6b3e\u836f\u7269\u83b7\u6279\u81f3\u4eca\u4e0d\u8db3\u4e24\u5e74\uff0cMenin\u9776\u70b9\u5feb\u901f\u4ece\u5355\u836f\u540e\u7ebf\u6cbb\u7597\u63a2\u7d22\u6f14\u53d8\u4e3a\u591a\u836f\u7269\u3001\u591a\u9002\u5e94\u75c7\u3001\u8054\u5408\u65b9\u6848\u5e76\u884c\u5f00\u53d1\u7684\u6fc0\u70c8\u7ade\u4e89\u683c\u5c40\u30022026\u5e746\u6708\uff0c\u6b27\u6d32\u8840\u6db2\u5b66\u4f1a\uff08EHA\uff09\u5e74\u4f1a\u4e0a\u516c\u5e03\u7684\u7cfb\u5217\u7814\u7a76\u6570\u636e\uff0c\u8fdb\u4e00\u6b65\u63a8\u52a8Menin\u6291\u5236\u5242\u4ece\u590d\u53d1\u96be\u6cbb\u633d\u6551\u6cbb\u7597\uff0c\u8fc8\u5411\u4e00\u7ebf\u8054\u5408\u8bf1\u5bfc\u3001\u79fb\u690d\u540e\u7ef4\u6301\u6cbb\u7597\u7684\u5168\u65b0\u9636\u6bb5[2]\u3002
\n\u672c\u6587\u4ece\u5206\u5b50\u673a\u5236\u3001\u5173\u952e\u4e34\u5e8a\u8bd5\u9a8c\u3001\u5b89\u5168\u6027\u7ba1\u7406\u3001\u8010\u836f\u6311\u6218\u53ca\u672a\u6765\u65b9\u5411\u4e94\u4e2a\u7ef4\u5ea6\uff0c\u5bf9\u8fd9\u4e00\u9776\u70b9\u8fdb\u884c\u5168\u666f\u5f0f\u68b3\u7406\u3002<\/p>\n","protected":false},"author":1,"featured_media":2042,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[147],"tags":[86,15,32,34],"class_list":["post-2041","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-147","tag-86","tag-15","tag-32","tag-34"],"_links":{"self":[{"href":"https:\/\/www.millibuff.com\/index.php?rest_route=\/wp\/v2\/posts\/2041","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.millibuff.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.millibuff.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.millibuff.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.millibuff.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2041"}],"version-history":[{"count":1,"href":"https:\/\/www.millibuff.com\/index.php?rest_route=\/wp\/v2\/posts\/2041\/revisions"}],"predecessor-version":[{"id":2043,"href":"https:\/\/www.millibuff.com\/index.php?rest_route=\/wp\/v2\/posts\/2041\/revisions\/2043"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.millibuff.com\/index.php?rest_route=\/wp\/v2\/media\/2042"}],"wp:attachment":[{"href":"https:\/\/www.millibuff.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2041"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.millibuff.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2041"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.millibuff.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2041"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}